Ameriprise
BHVN

Ameriprise’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Ameriprise’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-29,388
Closed -$4.44M – 4135
2022
Q3 		$4.44M Sell
29,388
-20,501
-41% -$3.04M ﹤0.01% 2306
2022
Q2 		$7.27M Buy
49,889
+5,844
+13% +$746K ﹤0.01% 2008
2022
Q1 		$5.22M Sell
44,045
-226
-0.5% -$28.2K ﹤0.01% 2394
2021
Q4 		$6.1M Sell
44,271
-4,738
-10% -$603K ﹤0.01% 2330
2021
Q3 		$6.81M Sell
49,009
-4,257
-8% -$532K ﹤0.01% 2168
2021
Q2 		$5.17M Buy
53,266
+2,095
+4% +$170K ﹤0.01% 2433
2021
Q1 		$3.5M Sell
51,171
-6,572
-11% -$532K ﹤0.01% 2607
2020
Q4 		$4.95M Sell
57,743
-13,376
-19% -$1.13M ﹤0.01% 2284
2020
Q3 		$4.62M Sell
71,119
-13,656
-16% -$895K ﹤0.01% 2137
2020
Q2 		$6.2M Sell
84,775
-5,484
-6% -$292K ﹤0.01% 1906
2020
Q1 		$3.07M Buy
90,259
+20,817
+30% +$952K ﹤0.01% 2235
2019
Q4 		$3.78M Buy
69,442
+5,030
+8% +$249K ﹤0.01% 2397
2019
Q3 		$2.69M Sell
64,412
-3,431
-5% -$145K ﹤0.01% 2549
2019
Q2 		$2.97M Sell
67,843
-10,328
-13% -$582K ﹤0.01% 2533
2019
Q1 		$4.02M Buy
78,171
+29,072
+59% +$1.26M ﹤0.01% 2361
2018
Q4 		$1.82M Buy
49,099
+13,552
+38% +$489K ﹤0.01% 2691
2018
Q3 		$1.33M Buy
+35,547
New +$1.31M ﹤0.01% 2963

Other funds holding BHVN

LIP
Liontrust Investment Partners London, United Kingdom $5.86B AUM 23.75% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $176M AUM 95.04% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
MSCM
McElhenny Sheffield Capital Management Dallas, Texas $404M AUM 19.8% 1-Year Est. Return

Ameriprise's BHVN Position: Q4 2022 in Review

Ameriprise sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2022, closing a stake of 29,388 shares — an estimated $4.44M sold.

Ameriprise first reported a position in BHVN in Q3 2018 and held it in 17 quarters. The position peaked at $7.27M in Q2 2022. 7 funds tracked by Wall St. Rank hold BHVN as of Q4 2022.

  • Ameriprise reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2022 after selling out during the quarter.
  • Ameriprise sold 29,388 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2022, an estimated $4.44M.
  • Ameriprise first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q3 2018 and held it in 17 quarters.
  • Ameriprise's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $7.27M in Q2 2022.
  • 7 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2022.

Based on Ameriprise's 13F filing for Q4 2022, filed 14 Feb 2023.